The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018–2019)

Bonanni, Paolo; Faivre, Pascaline; Lopalco, Pietro Luigi; Joura, Elmar A.; Bergroth, Tobias; Varga, Štefan; Gemayel, Nathalie; Drury, Rosybel

doi:10.1080/14760584.2020.1858057

Cited by 32 publications

(36 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Digene HC2 is able to differentiate only between 2 HPV DNA groups, low-risk (LR) and high-risk (HR) types. Where genotyping was performed, we defined HR+, LR+ or negative status according to the Anyplex™ II HPV28 Detection Seegene test-performed in Gemelli Hospital-in which HR types are 16,18,26,31,33,35,39,45,51,52,53,56,58,59,66,68,69,73,82;and LR types are 6,11,40,42,43,44,54,61,70. With the aim to include also the Digene HC2 results in our analysis, we decided to group the HPV results of the genotyping test as HPV HR+ when at least one HR genotype was identified, HPV LR+ when only LR genotypes were identified and HPV-negative when no HPV type was reported. Patients with an HR-HPV test and LSIL were histologically confirmed to be CIN1 or less after colposcopy-guided biopsy.…”

Section: Methodsmentioning

confidence: 99%

“…After the introduction of the 2017-2019 National Preventive Vaccination Plan (2017-2019 PNPV) [16], access to vaccination became active and free for all 12-year-old boys and adolescents, with the aim of universal HPV vaccination. Finally, since 2019, the Italian "Calendario Vaccinale della Vita" [17], adopted by general practitioners and some scientific societies, has suggested the possibility of an "opportunistic" vaccination in adult subjects as a personal preventive tool, without age limits [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study

et al. 2021

View full text Add to dashboard Cite

Background: This study evaluates the possible effect of 9-valent (9vHPV) vaccination on the results of HPV and cytological tests in a cohort of adult women. Methods: This study is a retrospective, single-cohort, monocentric study. Sexually active women aged 14–70 years, who underwent 9vHPV vaccination, were enrolled. Dose administration dates, side effects and data on Pap smears and HPV tests performed before and after the first vaccine dose were collected. Subjects were considered “unexposed” to the vaccine for all time intervals before the first dose administration, and “exposed” to the first, second and third vaccine doses in all time intervals following each specific dose. Results: A total of 512 women underwent the first 9vHPV dose administration and were enrolled in the study. Median age at vaccination was 30.5 (14–70). Log-rank tests and Cox regression analyses showed a highly statistically significant (p < 0.0001) difference in the time to negativization after the exposure to the third vaccine dose in the 207 women starting with a Pap+ smear (HR (95% C.I.), 2.66 (1.83–3.86)) and in the 198 women starting with an HPV HR+ test (HR (95% C.I.), 7.80 (4.83–12.60)). Conclusions: 9vHPV vaccination may play a role in shortening the clearance time of HPV HR+ or Pap positivity in sexually active adult women.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Empfehlungen zur HPV-Impfung gibt es inzwischen weltweit erst in 107 (55 %) der 194 WHO-Mitgliedsstaaten [ 23 ]. In den europäischen WHO-Ländern ist in 13 Ländern noch keine Impfempfehlung ausgesprochen und damit ist keine Erstattungsfähigkeit gegeben [ 24 ].…”

Section: Impfziel: Eliminierung Des Zervixkarzinomsunclassified

14 Jahre HPV-Impfung: was haben wir erreicht?

Wojcinski

2021

Gynäkologe

View full text Add to dashboard Cite

Professor Harald zur Hausen, „Vater der HPV(humane Papillomviren)-Impfung“, wurde in diesem Jahr 85 Jahre alt. Aus diesem Anlass wird in einem Rückblick auf die Einführung der HPV-Impfung vor 14 Jahren geschaut, und es werden die Widerstände aufgezeigt, welche die ersten Jahre dieser segensreichen Impfung begleiteten. Schon früh wurde 2007 die Impfung für die Mädchen in das Standardimpfprogramm der Ständigen Impfkommission am Robert Koch-Institut (STIKO) aufgenommen, erst 11 Jahre später kam es zur Empfehlung auch für Jungen. Die Impfquoten in beiden Gruppen sind mit ca. 50 % in Deutschland weiterhin im Vergleich zu anderen Ländern mit Schulimpfprogrammen zu niedrig. Dabei gibt es keine wissenschaftlichen Bedenken mehr gegenüber der HPV-Impfung, die sich in weltweiten Studien als sicher und wirksam erwiesen hat. Nicht nur die Verminderung der Krebsvorstufen, sondern auch von Zervixkarzinomen konnte neben der starken Reduktion von Fällen an Condylomata acuminata bei den Geimpften inzwischen in Real-Life-Studien gezeigt werden, weshalb die WHO (World Health Organization) als Impfziel die Eliminierung des Zervixkrebses durch Aufbau einer Bevölkerungsimmunität erklärt hat. Dazu sollten weitere Anstrengungen unternommen werden, die Impfquoten in Deutschland zu erhöhen, was auch in einem entsprechenden Appell der Gesundheitsministerkonferenz im Juni 2021 eingeflossen ist.

show abstract

“…1 , 7 , 8 Countries in Europe have had varying degrees of success with HPV prevention, with vaccination coverage rates ranging from 4% in Bulgaria to 94% in Portugal (2018). 9 Despite around 3,000 women being diagnosed with cervical cancer and 1,000 dying from the disease every year in France, 10 the country has one of the lowest HPV vaccination coverage in Europe, with only 24% of the targeted population having completed their course of HPV vaccination in 2019. 9 The routine HPV vaccination program started in France in 2007, targeting 11 to 14-year-old girls with a catch-up campaign for 15 to 19 year-old girls.…”

Section: Introductionmentioning

confidence: 99%

“We don’t have the same bodies; we don’t react the same way”: mothers and adolescent girls’ perceptions of the risks and benefits of HPV vaccination in France

Karafillakis

Peretti‐Watel

Verger

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Human Papillomavirus (HPV) vaccination is one of the most publicly mistrusted vaccines in Europe, with countries such as France struggling with low vaccine uptake due to parental questioning of vaccine risks and benefits. However, limited evidence exists on adolescent girls’ perceptions of the risks and benefits of HPV vaccination. The aim of this qualitative study was to provide an in-depth exploration and comparison of French mothers (n = 21) and adolescent girls’ (n = 36) perceptions of the risks and benefits of HPV vaccination. A thematic analysis showed that adolescent girls and mothers perceived the risks and benefits of HPV vaccination differently, with girls reporting positive and beneficial views and emotions toward vaccination and mothers expressing concerns about possible risks. Adolescent girls also reported that both perceptions and actual risks and benefits may vary from one individual to another. Vaccine safety was also understood differently, with mothers reporting a widespread view that vaccines are unsafe and focusing on controversial side effects and girls discussing short-term consequences of vaccination (e.g. pain, fever) and administration and storage issues. Strategies to improve uptake of HPV vaccination should consider and address both the mothers’ and daughters’ perceptions and understandings of HPV vaccination.

show abstract

The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018–2019)

Cited by 32 publications

References 16 publications

HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study

HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study

14 Jahre HPV-Impfung: was haben wir erreicht?

“We don’t have the same bodies; we don’t react the same way”: mothers and adolescent girls’ perceptions of the risks and benefits of HPV vaccination in France

Contact Info

Product

Resources

About